Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months.

CONCLUSION: Early treatment with rituximab can lead to higher rate of complete remission, a lower rate of disease relapse, and longer duration of complete remission in PV patients. PMID: 30081690 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research